Otros idiomas Travere Therapeutics, Inc.

Acciones

TVTX

US89422G1076

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 20/06/2025			Variación 5 días	Varia. 1 de enero.
14,31 ^USD	-0,69 %		-1,31 %	-17,85 %

12/06	Travere Therapeutics informa sobre la concesión de incentivos en virtud de la norma 5635(C)(4) de cotización del Nasdaq	RE
11/06	Travere Therapeutics, Inc. presentará nuevos datos sobre FILSPARI® (sparsentan) en la 15.ª Conferencia Internacional sobre Podocitos.	CI

Otros idiomas

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	12/06
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	12/06
Travere Therapeutics to Present New FILSPARI Data at the 15th International Podocyte Conference	12/06
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX	12/06
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference	11/06
Travere Therapeutics, Inc. to Present New FILSPARI® Data At the 15Th International Podocyte Conference	11/06
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day	10/06
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX	07/06
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress	03/06
Travere Therapeutics, Inc. to Present New FILSPARI®? Data At the 62nd ERA Congress	03/06
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX	01/06
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX	26/05
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX	21/05
Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease	16/05
Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease	15/05
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS	15/05
Travere Therapeutics Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS	15/05
Travere Therapeutics, Inc. Announces FDA Acceptance of sNDA for Filspari® in FSGS	15/05
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	12/05
Travere Therapeutics to Participate at Upcoming Investor Conferences	07/05
Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36	01/05
Travere Therapeutics : Q1 2025 Earnings Presentation	01/05
Travere: Q1 Earnings Snapshot	01/05
Earnings Flash (TVTX) Travere Therapeutics Reports Q1 Revenue $81.7M, vs. FactSet Est of $77.3M	01/05
Travere Therapeutics Reports First Quarter 2025 Financial Results	01/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Travere Therapeutics, Inc.

Acciones

TVTX

US89422G1076

Biotecnología e investigación médica

Otros idiomas

Filtros